Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease.
about
Bile acids for primary sclerosing cholangitisA review of the medical treatment of primary sclerosing cholangitis in the 21st centuryCholangiocyte cilia are abnormal in syndromic and non-syndromic biliary atresia.Implications of genome-wide association studies in novel therapeutics in primary biliary cirrhosisClinical application of transcriptional activators of bile salt transporters.Recurrent primary biliary cirrhosis: peritransplant factors and ursodeoxycholic acid treatment post-liver transplant.Medical treatment of cholestatic liver diseases: From pathobiology to pharmacological targets.INTRACELLULAR SIGNALING BY BILE ACIDS.The effect of ursodeoxycholic acid in liver functional restoration of patients with obstructive jaundice after endoscopic treatment: a prospective, randomized, and controlled study.Hydrophilic bile acids protect human blood-brain barrier endothelial cells from disruption by unconjugated bilirubin: an in vitro studyExpression and function of renal and hepatic organic anion transporters in extrahepatic cholestasis.Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis.Mechanisms of disease: mechanisms and clinical implications of cholestasis in sepsis.Role of the Nrf2-ARE pathway in liver diseasesThe unfinished business of primary biliary cirrhosisUrsodeoxycholic acid: Mechanism of action and novel clinical applications.The efficacy of pharmacological treatment in pediatric nonalcoholic Fatty liver disease.High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis.Serum bile acid profiling reflects enterohepatic detoxification state and intestinal barrier function in inflammatory bowel disease.Immune-mediated liver diseases: programmed cell death ligands and circulating apoptotic markers.UGT3A: novel UDP-glycosyltransferases of the UGT superfamily.Emerging pharmacologic therapies for primary sclerosing cholangitis.Child with Jaundice and Pruritus: How to Evaluate?Naturally Occurring Nrf2 Activators: Potential in Treatment of Liver Injury.Identification of UDP glycosyltransferase 3A1 as a UDP N-acetylglucosaminyltransferase.Substrate specificity of human ABCC4 (MRP4)-mediated cotransport of bile acids and reduced glutathione.Chemical chaperone, TUDCA unlike PBA, mitigates protein aggregation efficiently and resists ER and non-ER stress induced HepG2 cell death.Combined endoscopic and ursodeoxycholic acid treatment of biliary cast syndrome in a non-transplant patient.Effect of quercetin on CYP3A activity in Chinese healthy participants.Ursodeoxycholic acid stimulates Nrf2-mediated hepatocellular transport, detoxification, and antioxidative stress systems in mice.Adaptive responses of renal organic anion transporter 3 (OAT3) during cholestasis.Tauroursodeoxycholic acid inserts the bile salt export pump into canalicular membranes of cholestatic rat liver.The benign course of liver disease in adults with cystic fibrosis and the effect of ursodeoxycholic acid.Targeted pharmacotherapy in progressive familial intrahepatic cholestasis type 2: Evidence for improvement of cholestasis with 4-phenylbutyrate.Is ursodeoxycholic acid crucial for ischemia/reperfusion-induced ovarian injury in rat ovary?Ursodeoxycholate Restores Biliary Excretion of Methotrexate in Rats with Ethinyl Estradiol Induced-Cholestasis by Restoring Canalicular Mrp2 Expression.Liver disease in infancy caused by oxysterol 7 α-hydroxylase deficiency: successful treatment with chenodeoxycholic acidFunction of nuclear steroid receptors in apoptosis: role of ursodeoxycholic acid
P2860
Q24234678-A4F9E3E8-60A7-4778-A9DA-03BC09763396Q26771816-B5588683-89E2-4B14-85C6-7BE645F57B47Q30513913-B1290A7D-ADA5-41B3-B04A-AE21B103FC1CQ33579196-B34BFE51-F1A7-4469-8E0F-96873F45E6E3Q33709930-3F49D1FA-0622-4511-A1CF-5F5D3B3F017AQ33730935-7D2AEC3C-D95E-4567-AA89-2A22AFEB3AF7Q34017604-63888179-4BFC-42A4-9632-FE3CE4F9CA15Q34448448-F6C23762-A4D4-4357-8802-4BC448238555Q34993108-5A4FBE47-76E0-475E-BA13-E147525BBAC2Q35172521-9985CFFD-FC52-47C9-AA48-6D2D4D4D3F2FQ36429814-29301A10-78E7-4EAD-B276-9ADC14410D46Q36495172-3442EEB3-9EA6-4B5A-9DCE-CB6D2CC2E753Q36606886-C668ECE9-9075-4603-A537-32BDA0FFBC38Q36879950-91488A86-A64B-42A2-A720-45156D85427BQ36914332-46DB605A-7253-470A-ADA2-CDBB33DEA4A1Q37012207-65FAF433-8C29-40AB-84C9-9339542D090DQ37101542-5CD9476A-5996-496A-98B2-B3C54F39F77BQ37117971-9AD9C545-51C9-4679-A387-B3562D7EFEF5Q37250362-EC21E22B-3CC7-454F-8EB7-DD31FE3E132BQ37418054-ABAA1E84-51EC-4458-9B6D-E700825DB540Q37611031-1A49847A-5DE9-4440-8E5F-D06C11B0F319Q38751076-A4209C9D-B3D6-41BF-AC66-D031AD910BF3Q38757248-70E3FA80-2BE0-4CC7-A592-4DCD38AF6A76Q39094306-F34F74F0-22EA-4EF3-ACDB-39E9D998769FQ39921876-2D86C85E-1589-4F48-895F-D72A98B61080Q40352370-FABA69E8-8328-4605-AFDF-3BA7C15E93A9Q41095627-8A88EE15-F2AB-4A4E-A17E-7A4C894093EAQ42555450-9FB76988-6C43-40F4-9FF7-B8BB5FA6774AQ42605353-155DA91E-8D2E-472B-BD7B-200214D2B66EQ46440176-CE96AA3C-8761-4541-BFB3-F32A53EA8A4BQ46595753-FA6DE7EE-7E21-4FE1-B9AA-BDF87EEF7189Q46848216-3F6E7F58-F253-4DC9-B705-EC4D88DF58BBQ46884201-78E70564-1004-4456-8E7A-65CE0417DD0AQ50438744-BDD10899-CB2A-40C8-A145-AE3C70F6405DQ53622503-EB100628-066F-4D47-B7DB-F418DB168A48Q55365658-6DC37C62-59DB-48C7-B745-62B62DB0D182Q57150403-11EAA904-1009-4191-A99D-A7C6DE3FA63DQ57760186-E38576FA-6D7D-4311-A158-FA6FA94DB528
P2860
Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Mechanisms of action and thera ...... in cholestatic liver disease.
@ast
Mechanisms of action and thera ...... in cholestatic liver disease.
@en
type
label
Mechanisms of action and thera ...... in cholestatic liver disease.
@ast
Mechanisms of action and thera ...... in cholestatic liver disease.
@en
prefLabel
Mechanisms of action and thera ...... in cholestatic liver disease.
@ast
Mechanisms of action and thera ...... in cholestatic liver disease.
@en
P1476
Mechanisms of action and thera ...... in cholestatic liver disease.
@en
P2093
Gustav Paumgartner
Ulrich Beuers
P304
P356
10.1016/S1089-3261(03)00135-1
P577
2004-02-01T00:00:00Z